Live vaccine, "ks" against classical swine fever and method of prevention of classical swine fever


(57) Abstract:

The invention relates to biotechnology and the receipt of the vaccine and method of prevention of classical swine fever. The vaccine contains an attenuated strain "CS" of classical swine fever virus and milk powder as a stabilizer. The vaccine has a high activity against classical swine fever and the introduction of high doses can eliminate the disease in disadvantaged large pig farms. 2 S. and 1 C.p. f-crystals.

The invention relates to biotechnology and related to vaccines for the prevention and treatment of classical swine fever (CSF). For specific prevention CoES known vaccine "LK-Vniivvim" containing lepidosirenidae Chinese vaccine strain "C" obtained by adaptation and reproduction of it in the culture of testicular tissue of lambs (EN 2064302C, A 61 K 39/187, 27.07.96) (C. S. Romanov). A disadvantage of the known vaccine and method of its application is the inability to liquidate CoES disadvantaged farms industrial type.

The invention consists also in the fact that the vaccine is given in high doses repeatedly. Repeated introduction of the vaccine in large doses (hyperbac the acquisition is a significant increase in the activity of a live vaccine against CSF and its applicability to the elimination of disease in large pig farms.

The invention consists in the following. The vaccine contains an attenuated strain "KC" virus CoES and stabilizer (medium dry).

Vaccine "KC" is a dry porous mass of white obtained by lyophilization of the mixture vaccinated culture liquid with medium drying. Mass fraction of moisture in the dry vaccine is in the range of 1-4%. Dry vaccine in vacuum bottles at 2-6oC preserves the original activity of not less than 12 months. During preventive vaccination a single dose of the vaccine "KC" is equal to 1000 IPD50and with the elimination of CSF - 100000-1000000 IPD50.

The strain KC received from the Chinese lepidosirenidae strain "C" virus CSF through a long passage and breeding in culture cells of porcine origin. Phenotypic strain "KC" is different from the vaccine strain "C" that does not cause hyperthermic response in rabbits when administered intravenously. It belongs to the genus of pestiviruses, family flaviviruses. The virion diameter of 40-60 nm; floating density of 1.12-1.13 g/cm3; sedimentation coefficient 140S. The genome consists of 12300 nucleotides and encodes polyprotein from 4000 amino acids. The genome of strain KC" differs from the genome of other known which of the 3 virion glycoprotein with a molecular mass of 23-57 KD. Nucleocapsid contains protein with molecular weight of 25 KD. For the synthesis of neutralizing antibodies and protective immunity responsible glycoprotein with a molecular mass of 55 KD.

Safety and immunogenicity of the strain "KC" fully meets the requirements of O. I. E. (OIE) and is different from the vaccine strains ("C", "GP", "Thiverval" and others) only a higher concentration of the virus obtained by reproduction in cell culture (1 ml not less than 108doses of infecting a cell culture - 108TCID50/ml).

Strain "KC" has the following biological properties:

breeds without cytopathic effect;

detected using antibodies labeled with peroxidase (PLA) or polymerase chain reaction (PCR);

safe for pigs of any age, including pregnant sows and newborn piglets;

not reversible (6 consecutive passages of the vaccine virus on bezmoroznyj pigs);

does not cause persistence in vaccinated pigs and rapidly disappears from the blood (7-10 days);

quickly (3-4 days) creates a long stressful immunity (not less than 2 years, the period of observation);

free from contamination by viruses, bacteria, fungi and Mikayla sjonnie trials have confirmed full compliance with strain, "KC" requirements and was the basis for its Deposit in the collection of microbial cultures VGNKI. Strain "KC" assigned registration number: the strain KC-DEPT".

The invention is illustrated by the following examples.

Example 1. For the preparation of vaccines using strain "KC", which is propagated in cell culture. Culture the virus combined with medium drying in the ratio required for obtaining vaccines with a given immunogenic activity. The resulting mixture was poured into 1 ml vials with a capacity of 3 ml and subjected to lyophilization. Vials with dry vaccine under vacuum hermetically closed with rubber stoppers and running aluminum caps.

Example 2. Under optimal culture conditions (a method of growing cells and virus multiplicity of infection, duration of incubation, treatment of infected culture) accumulation of strain KC reaches a high level of 8.0 to 9.2 lg TCID50/mlthat 100-1000 times the titer of all known vaccine strains used in the manufacture of live vaccines against CSF. The high degree of correlation of biological activity of strain KC" during the titration in cell cultures PK-15 (PLA, TCID50/mland during the titration on the pigs (IPD50/ml- immunizing dose that protects 50% of the vaccinated pigs). 1 IPD50<" studying the effects of various stabilizing environments and mode lyophilization. As cryoprotectants used widely used for these purposes, ingredients: sucrose, lactose, mannitol, gelatin, peptone, hydrolyzed lactalbumin, etc. the Use of these substances in various combinations and concentrations allows to stabilize the vaccine, although its infectious (immunogenic) activity was decreased by 1.3 to 2.5 lg. The use of dry cow's milk as createsite environment was preferred. Reducing the infectious activity of the vaccine does not exceed 0,7-1,0 lg. Drying vaccine "KC" with such a protective environment showed a high reproducibility of the results. So out of 30 episodes dry vaccine 27 series had the activity of 7.2 to 7.7 lg TCID50/mlrest - 6,7-7,0 lg TCID50/ml. At 2-6oC dry vaccine almost kept the original activity within 12 months.

Example 4. Epizootic activity of the vaccine "KC" was tested in two farms of industrial type (25000-27000 pigs; reproduction-fattening) affected with CSF.

In both farms CSF flowed the same type on the background of systematic preventive vaccine immunization LK-Vniivvim according to the instruction and was mainly characterized by a high incidence (40-50%) and death (25-30%) paino "KC" in higher doses and terms provided guidance on its application. As a result of hyperventilatie for 8-10 months of the disease CoES stopped. Thus, it was proved that in large disadvantaged farms CoES can be eliminated only by hyperventilatie. This goal can be achieved if the dose exceeds the usual 100 or more times and if hyperactivate is carried out within a certain timeframe.

1. Vaccine against classical swine containing an attenuated strain of the virus swine fever and stabilizer, characterized in that the attenuated strain it contains a strain VGNKI N "COP-DEPT" swine fever virus with a titer of infectious activity of 7.0 lg TCID50/mland more.

2. The vaccine under item 1, characterized in that it contains stabilizers skimmed cow's milk.

3. Method of prevention of classical swine fever, including intramuscular vaccine, wherein the vaccine is used vaccine under item 1 and enter its pigs in dysfunctional households repeatedly in large doses 100000 - 1000000 IPD50(hyperventilate).


Same patents:

The invention relates to veterinary Virology and biotechnology, and in particular to methods of obtaining living culture vaccines against distemper, and can be used at the enterprises of biological industry

The invention relates to medical Virology and can be used in health care for the prevention of epidemic influenza in adults and children live intranasal influenza vaccine from strain B/60/St. Petersburg/95/20

The invention relates to medical Virology and can be used in health care for the prevention of epidemic influenza in adults live intranasal influenza vaccine from strain A/17/Nanchang/95/4 (НЗN2)

The invention relates to veterinary Virology and biotechnology and can be used in the manufacture of tools for the specific prevention of infectious bursal disease (IBD) birds
The invention relates to medical Microbiology

The invention relates to the treatment of retroviral infections, more specifically to the treatment of infection with human immunodeficiency virus (HIV) and related diseases, including acquired immunodeficiency syndrome (AIDS)

The invention relates to the field of veterinary Virology in particular to testing of viral antigens, and can be used in the development and application of funds for the specific prevention of African swine fever

The invention relates to biotechnology, namely the genetic engineering of animals, and can be used in veterinary Virology for the detection of infectious diseases of farm animals, in particular, classical swine fever (CSF)
The invention relates to the field of biotechnology and veterinary Virology, in particular strain of classical swine fever virus used for production lepidosirenidae VirusWall against this disease

The invention relates to veterinary Virology, namely the method of preparation of inactivated culture vaccine for the prevention of rinderpest (cattle)

FIELD: biotechnology.

SUBSTANCE: the suggested vaccine contains suspension of viable spores of anthracic vaccinal strain "55-VNIIBB&M" at initial concentration of 500-700 mln. spores/, cultural virus-containing raw material of vaccinal virus of cattle plague of "LT" strain at activity of not less than 7.0 lg TCD50/cu. cm, lactosopeptonic stabilizing agent and distilled water at the following content of components,%: spores of anthracic strain "55-VNIIVV&M" -6.2 - 10.0; cultural raw material of cattle plague virus of "LT" strain -25.0 - 30.0; lactosopeptonic stabilizing agent -48.0 - 50.0; distilled water - the rest. One vaccinal dosage contains about 20-25 mln. anthracic spores and about 4.5-5.5 lg TCD50 of cattle plague virus The suggested vaccine is of high immunogenicity, develops tense immunity in once vaccinated cattle that lasts for 12 mo, not less, moreover, it is areactogenous, safe and stable at storage.

EFFECT: higher efficiency.

3 ex, 3 tbl

FIELD: medicine, veterinary.

SUBSTANCE: claimed invention relates to field of veterinary and describes chimeric vaccine antigen against classical swine plague virus (CSPV), characterised by the fact that it consists of extracellular segment of glycoprotein E2 of CSPV viral envelop on N-end of chimeric antigen and extracellular domain of swine CD 154 molecule, identified as SEQ ID NO: 2, on C-end of chimeric antigen. Chimeric antigens can be obtained in expression systems, which guarantee proper folding of tertiary structure of chimeric molecules. Vaccine compositions, which contain such chimeric antigens, cause early and strong immune response in vaccinised swine and create complete protection against CSPV. Chimeric antigens like obtained compositions, can be applied in veterinary as vaccines for preventive application in swine.

EFFECT: obtained vaccine compositions prevent transmission of virus from sows to their offspring.

10 cl, 11 dwg, 1 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to virology and concerns an attenuated strain of serotype 2 African swine fever virus (ASF). The strain is prepared by adaptation to PPK-666 cell culture for 50 passages followed by virus selection by limiting dilution in this culture and CMS cells, and deposited in the collections of microorganism strains of the State Scientific Institution of Russian National Research Institution of Veterinary Virology and Microbiology of the Russian Academy of Agricultural Sciences, No. 183.

EFFECT: presented strain is applicable in the research and diagnostic centres for the purpose of epizootological monitoring, virological, molecular-genetic researches and development of diagnostic and vaccine preparations in ASF.

3 tbl, 3 ex